Home
Live Updates
Ipsen Pharma: Ipsens Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis : vimarsana.com
Ipsen Pharma: Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver
Related Keywords
Paris ,
France General ,
France ,
Macau ,
United States ,
China ,
United Kingdom ,
Washington ,
Hong Kong ,
Taiwan ,
American ,
Christelle Huguet ,
Rachel Reiff ,
Kris Kowdley ,
Nicolas Bogler ,
Anna Gibbins ,
Amy Wolf ,
Carol Roberts ,
Clin Gastroenterol Hepatol ,
Ipsen Euronext ,
Ipsen Pharmaceuticals Inc ,
Regulatory Agency ,
Liver Institute ,
Head Of Research ,
Drug Administration ,
Fibrotic Liver Disease Consortium Investigators ,
Ipsen Pharmaceuticals ,
Newborn Development ,
European Medicines Agency ,
Executive Vice President ,
New England Journal ,
Important Safety Information ,
Liver Institute Northwest ,
Executive President ,
United Kingdom Medicines ,
Induced Liver Injury ,
Adverse Event ,
Reproductive Potential ,
Prescribing Information ,
Breakthrough Therapy Designation ,
Rare Disease ,
Sponsored Leveli American Depositary Receipt ,
French Autorit ,
Des March ,
Universal Registration Document ,
Primary Biliary ,
Liver Disease Consortium ,
Increasing Prevalence ,
Primary Biliary Cholangitis ,
Reduced Mortality With ,
Clin Gastroenterol ,
Ihr Portfolio ,
vimarsana.com © 2020. All Rights Reserved.